• 1
    Gilbert SM, Wood DP, Dunn RL et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 2007; 109: 175662
  • 2
    Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 8993
  • 3
    Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16: 1298301
  • 4
    Shelley MD, Barber J, Wilt T, Mason MD. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002; (1): CD002079
  • 5
    Hagan MP, Winter KA, Kaufman DS et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 66572
  • 6
    Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 306171
  • 7
    Shipley WU, Kaufman DS, Zehr E et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 627; discussion 7–8
  • 8
    Shipley WU, Prout GR Jr, Einstein AB et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987; 258: 9315
  • 9
    Tester W, Porter A, Asbell S et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25: 78390
  • 10
    Weiss C, Engehausen DG, Krause FS et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68: 107280
  • 11
    Dalbagni G, Genega E, Hashibe M et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 11116
  • 12
    Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 66675
  • 13
    Zietman AL, Sacco D, Skowronski U et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170: 17726
  • 14
    Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 29017
  • 15
    Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40: 1217
  • 16
    Koga F, Kihara K, Fujii Y et al. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int 2009; 104: 18994
  • 17
    Koga F, Kihara K, Yoshida S et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int 2011; DOI:10.1111/j.1464-410X.2011.10425.x. [Epub ahead of print]
  • 18
    Koga F, Yoshida S, Kawakami S et al. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis. Urology 2008; 72: 3848
  • 19
    Yoshida S, Koga F, Kawakami S et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75: 38791
  • 20
    Kihara K, Kawakami S, Fujii Y, Masuda H, Koga F. Gasless single-port access endoscopic surgery in urology: minimum incision endoscopic surgery, MIES. Int J Urol 2009; 16: 791800
  • 21
    Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009; 22 (Suppl. 2): S7095
  • 22
    Sobin LH, Wittekind C eds. Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002
  • 23
    Cohen SM, Goel A, Phillips J, Ennis RD, Grossbard ML. The role of perioperative chemotherapy in the treatment of urothelial cancer. Oncologist 2006; 11: 63040
  • 24
    Paz-Ares LG, Solsona E, Esteban E et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010; 28: LBA4518
  • 25
    Holzbeierlein JM, Lopez-Corona E, Bochner BH et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004; 172: 87881
  • 26
    Kassouf W, Swanson D, Kamat AM et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 2006; 175: 205862
  • 27
    Bryne M, Boysen M, Alfsen CG et al. The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res 1998; 18: 475764
  • 28
    Koga F, Kageyama Y, Kawakami S et al. Prognostic significance of endothelial Per-Arnt-sim domain protein 1/hypoxia-inducible factor-2alpha expression in a subset of tumor associated macrophages in invasive bladder cancer. J Urol 2004; 171: 10804